ARI terminations start again.

Quote
Anonymous said:
The House has just passed a bill that would ban corporate execs from doing business with Medicare and Medicaid if their companies were convicted of fraud. The measure also gives the Department of Health & Human Services Office of the Inspector General the ability to exclude parent companies that may be committing fraud through shell companies, which are otherwise known in polite circles as subsidiaries.
The legislation was designed to close a pair of loopholes in existing law. Currently, execs at companies that are convicted of fraud can be excluded from federal health care programs, but if an exec had left the company by the time of conviction, there was no mechanism to enforce a ban. Now, the HHS OIG can ban execs from doing business with these programs, even if they later work elsewhere. The bill (look here) would apply to anyone who maintained an ownership stake or controlling interest in the fraudulent company
And since companies often set up subsidiaries to insulate themselves from liability, the HHS OIG can now exclude the parent companies from the Medicare and Medicaid programs. Pfizer, for instance, created subisidiaries that pleaded guilty last year to off-label marketing several drugs and paid a $2.3 billion fine (see here).
The growing number of fraud cases - several of which have involved big drugmakers that paid huge fines - have drawn criticism, because the companies have been permitted to continue to do business with federal health plans, yet individual execs have rarely been held accountable. Examples include AstraZeneca, Eli Lilly, Allergan and Forest Laboratories.
One notable exception occurred three years ago, when Purdue Pharma and three execs pleaded guilty in federal court in Virginia to criminal charges for misleading regulators, doctors and consumers about the addictive risks of Oxycontin (back story). Since then, the execs have been fighting the ban (see this).
The bill, which was proposed last week by two California congressmen - Pete Stark, a Democrat, and Wally Herger, a Republican - came in response to requests made by Lewis Morris, the HHS OIG chief counsel, during testimony last June before a joint hearing of the Ways and Means subcommittees on Health and Oversight. He made a point of directing the committees to the loopholes (see a few of his comments here). The bill had 19 co-sponsors, by the way. Although the effort will amount to naught if the Senate fails to act, supporters were encouraged.
“What we have going on now in health care sentencing is ridiculous,” says Patrick Burns of Taxpayers Against Fraud, a non-profit that supports the lawsuits. “For the little stealing, they put you in jail and exclude you from Medicare and Medicaid for life. For the big stealing, no one goes to jail and they let you carry on with the same marketing team in place. Top executives get nine-figure Golden Parachutes, and only the whistleblower loses his or her job. That has to change, and wheels are already rolling in that direction…It’s time we excluded top executives in these companies. If we can get regime change in Iraq, Afghanistan and General Motors, I’m pretty sure we can get regime change at Pfizer, Astra-Zeneca and Tenet.”
“This bill is an important, bipartisan measure that will protect Medicare beneficiaries and taxpayers,” Stark says in a statement. “It closes two loopholes that allow executives and corporations who defraud Medicare to keep doing business. I thank my colleagues for their support, and I urge the Senate to pass this bill.” Says Herger: “With these additional tools, OIG will be better able to stop those individuals who commit fraud but who have been able to stay one step ahead of law enforcement, saving taxpayer dollars and protecting seniors.”
Click to expand...


Its about god dam time!
 


















Quite simple! Even if Amgen gets the go ahead on Prolia, it has been so heavily hyped, that the shares may respond just a little higher.

Keep in mind, the sales have been [very] slow which means there could be sales department thinning, even with the FDA approval.
 












Anonymous said:
Quite simple! Even if Amgen gets the go ahead on Prolia, it has been so heavily hyped, that the shares may respond just a little higher.

Keep in mind, the sales have been [very] slow which means there could be sales department thinning, even with the FDA approval.
Click to expand...

Physicians are not crazy about using long term acting drugs for the simple reason that if they prescribe a drug for something and that person has an adverse reaction to that drug that drug the doctor just gave that person is going to last six month now what is there an antidote to counter act the reaction ? So now the doctor has to treat for a reaction for six months rather with short term acting drug which in a case of an adverse reaction the doctor can simple stop the treatment and the effects go away. Doctors I think are not going to be so quick to jump on with this drug when ther are other options.
 




























































Anonymous said:
what is up with ARI and wrongful terminations??????
Click to expand...

It has been on going for years i have seen it to many times and the troubled people are still there. Wait and see what happens in the next couple of weeks!!!!!!! management has been told to look for weak links to reduce head count.
Let the ass kissing begin.
 






Anonymous said:
It has been on going for years i have seen it to many times and the troubled people are still there. Wait and see what happens in the next couple of weeks!!!!!!! management has been told to look for weak links to reduce head count.
Let the ass kissing begin.
Click to expand...

Sounds like it is starting again. Get a good lawyer!!!!!
 






Top Bottom
Back
Quote